Evidence map›Paper›PMID 42253854›Full record

ArticleCancer innovation2026

Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition).

Fei Ma, Binghe Xu, China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplastic Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, Expert Committee on Chemotherapy Quality Control of Beijing Cancer Treatment Quality Control and Improvement Center

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer innovation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fei MaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.ORCID https://orcid.org/0000-0001-9432-1902
Binghe XuDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplastic Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, Expert Committee on Chemotherapy Quality Control of Beijing Cancer Treatment Quality Control and Improvement Center

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer represents a major threat to women's health in China. Its continuously rising incidence contributes to a growing disease burden, thereby creating a critical demand for novel and effective therapeutic strategies. In recent years, poly ADP-ribose polymerase (PARP) inhibitors, as a novel class of anti-tumor drugs targeting the DNA damage repair pathway, have demonstrated remarkable efficacy in treating breast cancer with

Indexed as

breast cancerclinical applicationPARP inhibitorssafety managementtargeted therapy

Identifiers

PMID42253854
PMCPMC13238854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.